Copyright
©The Author(s) 2017.
World J Hepatol. Feb 18, 2017; 9(5): 227-241
Published online Feb 18, 2017. doi: 10.4254/wjh.v9.i5.227
Published online Feb 18, 2017. doi: 10.4254/wjh.v9.i5.227
NAs (approval year) | Class effect | Renal effect | Most common adverse events | Laboratory monitoring | Rare severe adverse reactions | Pregnancy category | Detection in breastfeeding |
Lamivudine (1998) | Myopathy and neuropathy cases were reported | No significant effect | Upper respiratory tract infection, nasopharyngitis, headache and fatigue ALT flairs CK elevation may occur (usually not requiring cessation of drug) | Serum ALT and bilirubin | Rhabdomyolysis, acute dystonia, pancreatitis Rare lactic acidosis | C | Yes |
Telbivudine (2006) | Myopathy and neuropathy cases were reported (especially in combination with Peg- IFN) | Nephroprotective effect Increase in GFR | Upper respiratory tract infection, nasopharyngitis, headache and fatigue Increased incidence of CK elevation (usually asymptomatic and self-limiting, not required cessation of drug) | CK level Serum lactate | Lactic acidosis | B | Yes |
Adefovir (2002) | Very rare, No increased incidence of myopathy compared to placebo | Clinically significant nephrotoxicity Decrease in GFR | Pharyngitis, asteni, headache, abdominal pain, flu-like symptoms and nausea | Serum creatinine and phosphate level | Hypophosphatemia Fanconi syndrome | C | Unknown, not recommend for use |
Entecavir (2005) | Very rare, No increased incidence of mitochondrial toxicity in combination of entecavir with other NAs and IFN | No decrease in GFR | Headache, upper respiratory tract infection, cough, nasopharyngitis, fatigue, dizziness, upper abdominal pain and nausea | Serum lactate | Lactic acidosis | C | Unknown, not recommend for use |
Tenofovir (2008) | Very rare, No increased incidence of myopathy compared to placebo | May decrease GFR, clinically insignificant Nephrotoxic in HIV patients Hypophosphatemia | Headache, nasopharyngitis, back pain, nausea Bone mineral density loss (more prominent in HIV patients) | Serum creatinine and phosphate level BMD | B | Yes |
- Citation: Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol 2017; 9(5): 227-241
- URL: https://www.wjgnet.com/1948-5182/full/v9/i5/227.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i5.227